NTLA
Intellia Therapeutics Inc

14,010
Mkt Cap
$1.32B
Volume
20.09M
52W High
$28.25
52W Low
$5.90
PE Ratio
-2.63
NTLA Fundamentals
Price
$9.09
Prev Close
$12.32
Open
$9.14
50D MA
$17.23
Beta
1.71
Avg. Volume
10.01M
EPS (Annual)
-$5.25
P/B
1.81
Rev/Employee
$143,615.39
Loading...
Loading...
News
all
press releases
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
Zacks·6h ago
News Placeholder
More News
News Placeholder
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +9.80% and -12.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·22h ago
News Placeholder
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
Zacks·2d ago
News Placeholder
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
Zacks·2d ago
News Placeholder
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
Zacks·3d ago
News Placeholder
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
Zacks·3d ago
News Placeholder
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.
Zacks·3d ago
News Placeholder
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.
Zacks·4d ago
News Placeholder
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
Zacks·7d ago
News Placeholder
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7d ago

Latest NTLA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.